Mydriacyl tropicamide 10 mg/mL Solution/ Drops — NDC 0065-0355-03 (Billing 00065-0355-03)
This is a package of Mydriacyl tropicamide 10 mg/mL Solution/ Drops from Alcon Laboratories, Inc., marketed since Apr 1959 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 0065-0355-03 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 0065 labeler · 0355 product · 03 package
- Package marketed since
- Apr 1, 1959
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC)
- 0300650355032
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 007873
- GCN: 33021
- HICL (First Databank): 003466
- AHFS class code: 52:24.00.00
- RxCUI (RxNorm): 208660
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Anticholinergic class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
Tropicamide ophthalmic is used to cause pupil dilation (making the black center of the eye bigger) before an eye examination. Tropicamide is in a class of medications called mydriatics. It works by relaxing certain muscles in the eye.
Read the full MedlinePlus article ↗Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 4, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 00065-0355-03 You're viewing this Main listing | 1 BOTTLE in 1 CARTON / 3 mL in 1 BOTTLE | 1959-04-01 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Tropicamide 10 mg/mL 70069-0121-01 | Somerset | 1 bottle | $0.552 | AT | Availability likely | — |
| Tropicamide 10 mg/mL 61314-0355-01 | Sandoz | 1 bottle | $2.635 | AT | Availability likely | — |
| Mydriacyl 10 mg/mLthis 00065-0355-03 | Alcon | 1 bottle | — | AT | FDA listed | — |
| Mydriacyl 10 mg/mL 00998-0355-15 | Alcon | 1 bottle | — | AT | FDA listed | — |
| Tropicamide 10 mg/mL 24208-0585-59 | Bausch | 1 bottle | — | AT | FDA listed | — |
| Tropicamide 10 mg/mL 85766-0040-15 | Sportpharm | 1 bottle | — | AT | FDA listed | — |
| Tropicamide 10 mg/mL 85766-0278-15 | Sportpharm | 1 bottle | — | AT | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII F5UM2KM3W7
Benzalkonium chloride is a chemical compound that works as a preservative and antimicrobial agent in medications. It prevents bacterial and fungal growth in liquid formulations to keep the product safe during storage and use.
-
UNII 7FLD91C86K
Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
-
UNII QTT17582CB
A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
-
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
-
UNII 55X04QC32I
A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
6 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 3, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Alcon Laboratories, Inc. labeler code 00065
- MIOSTAT carbachol .1 mg/mL Solution NDC 0065-0023-15
- Naphcon A naphazoline hydrochloride and pheniramine maleate .25 mg/mL; 3 mg/mL Solution/ Drops NDC 0065-0085-15
- FLUORESCITE fluorescein sodium 100 mg/mL Injection, Solution NDC 0065-0092-65
- Isopto Atropine atropine sulfate 10 mg/mL Solution NDC 0065-0303-55
- Phenylephrine Hydrochloride 100 mg/mL Solution/ Drops NDC 0065-0343-02
- Phenylephrine Hydrochloride 25 mg/mL Solution/ Drops NDC 0065-0349-04
- Cyclomydril cyclopentolate hydrochloride and phenylephrine 2 mg/mL; 10 mg/mL Solution/ Drops NDC 0065-0359-02
- Cyclogyl cyclopentolate hydrochloride 5 mg/mL Solution/ Drops NDC 0065-0395-15
- Cyclogyl cyclopentolate hydrochloride 10 mg/mL Solution/ Drops NDC 0065-0396-02
- Cyclogyl cyclopentolate hydrochloride 20 mg/mL Solution/ Drops NDC 0065-0397-02
- Alcon Tears Lubricant Eye Drops hypromellose 2910 2910 (4000 MPA.S) 5 mg/mL Solution/ Drops NDC 0065-0408-72
- Betadine povidone-iodine 5 mg/mL Solution NDC 0065-0411-30
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE For mydriasis and cycloplegia for diagnostic procedures.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION For refraction, instill one or two drops of 1% solution in the eye(s), repeated in five minutes. If patient is not seen within 20 to 30 minutes, an additional drop may be instilled to prolong mydriatic effect. For examination of fundus, instill one or two drops of 0.5% solution 15 or 20 minutes prior to examination.
Individuals with heavily pigmented irides may require higher strength or more doses. Mydriasis will reverse spontaneously with time, typically in 4 to 8 hours. However, in some cases, complete recovery may take up to 24 hours.
⛔ Contraindications ▾
CONTRAINDICATIONS Contraindicated in persons showing hypersensitivity to any component of this preparation.
⚠️ Warnings ▾
WARNINGS FOR TOPICAL OPHTHALMIC USE ONLY. NOT FOR INJECTION. This preparation may cause CNS disturbances which may be dangerous in pediatric patients. The possibility of psychotic reactions and behavioral disturbances due to hypersensitivity to anticholinergic drugs should be considered. Mydriatics may produce a transient elevation of intraocular pressure. Remove contact lenses before using.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Ocular: Transient stinging, blurred vision, photophobia and superficial punctate keratitis have been reported with the use of tropicamide. Increased intraocular pressure has been reported following the use of mydriatics. Non-Ocular: Dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide.
Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse in children have been reported with the use of anticholinergic drugs.
🔄 Drug Interactions ▾
Drug Interactions Tropicamide may interfere with the antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
🤰 Pregnancy ▾
Pregnancy Animal reproduction studies have not been conducted with tropicamide. It is also not known whether tropicamide can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Tropicamide should be given to a pregnant woman only if clearly needed.
🧒 Pediatric Use ▾
Pediatric Use Tropicamide may rarely cause CNS disturbances which may be dangerous in pediatric patients. Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse in children have been reported with the use of anticholinergic drugs (see WARNINGS ). Keep this and all medications out of the reach of children.
🧓 Geriatric Use ▾
Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the ciliary muscle to cholinergic stimulation, dilating the pupil (mydriasis). The stronger preparation (1%) also paralyzes accommodation. This preparation acts in 15-30 minutes, and the duration of activity is approximately 3-8 hours.
Complete recovery from mydriasis in some individuals may require 24 hours. The weaker strength may be useful in producing mydriasis with only slight cycloplegia. Heavily pigmented irides may require more doses than lightly pigmented irides.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED 3 mL and 15 mL in plastic DROP-TAINER® dispensers. 0.5% 15 mL: NDC 0998-0354-15 1% 3 mL: NDC 0065-0355-03 15 mL: NDC 0998-0355-15 STORAGE: Store at 8°C to 27°C (46°F-80°F). Do not refrigerate or store at high temperatures. Keep container tightly closed. Rx Only
📋 Description ▾
DESCRIPTION MYDRIACYL ® (tropicamide ophthalmic solution, USP) is an anticholinergic prepared as a sterile topical ophthalmic solution in two strengths. The active ingredient is represented by the chemical structure: Each mL of MYDRIACYL ® (tropicamide ophthalmic solution, USP) contains: Active: tropicamide 0.5% or 1%. Preservative: benzalkonium chloride 0.01%.
Inactives: sodium chloride, edetate disodium, hydrochloric acid and/or sodium hydroxide (to adjust pH), purified water; pH range 4.0-5.8. chemical
💬 Information for Patients ▾
Information for Patients Do not touch dropper tip to any surface, as this may contaminate the solution. Patient should be advised not to drive or engage in potentially hazardous activities while pupils are dilated. Patient may experience sensitivity to light and should protect eyes in bright illumination during dilation.
Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration.
⚠️ Precautions ▾
PRECAUTIONS General The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to reduce excessive systemic absorption. Information for Patients Do not touch dropper tip to any surface, as this may contaminate the solution. Patient should be advised not to drive or engage in potentially hazardous activities while pupils are dilated.
Patient may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child's mouth and to wash their own hands and the child's hands following administration. Drug Interactions Tropicamide may interfere with the antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
Carcinogenesis, Mutagenesis, Impairment of Fertility There have been no long-term studies done using tropicamide in animals to evaluate carcinogenic potential. Pregnancy Animal reproduction studies have not been conducted with tropicamide. It is also not known whether tropicamide can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
Tropicamide should be given to a pregnant woman only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when tropicamide is administered to a nursing woman.
Pediatric Use Tropicamide may rarely cause CNS disturbances which may be dangerous in pediatric patients. Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse in children have been reported with the use of anticholinergic drugs (see WARNINGS ). Keep this and all medications out of the reach of children.
Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
Carcinogenesis, Mutagenesis, Impairment of Fertility There have been no long-term studies done using tropicamide in animals to evaluate carcinogenic potential.
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL NDC 0065-0355-03 ALCON ® DROP-TAINER ® DISPENSER UNIT OF USE Mydriacyl ® 1 % (tropicamide ophthalmic solution, USP) 3 mL Sterile INGREDIENTS: Each mL contains: Active: Tropicamide 1%. Preservative: benzalkonium chloride 0.01%. Inactives: sodium chloride, edetate disodium, hydrochloric acid and/or sodium hydroxide (to adjust pH), purified water. pH range 4.0-5.8 Rx Only USUAL DOSAGE: One or two drops topically in the eye(s).
Read enclosed insert. STORAGE: Store at 8°-27°C (46°-80°F). Do not refrigerate or store at high temperatures.
Keep container tightly closed. © 2004, 2010 Alcon, Inc. Alcon ® ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA Printed in USA 350544-0210 LOT: EXP.: NDC 0065-0355-03 ALCON ® Mydriacyl ® (tropicamide ophthalmic solution USP) 1 % 3 mL Sterile Rx Only INGREDIENTS: Each mL contains: Active: Tropicamide 1%.
USUAL DOSAGE: One or two drops topically in the eye(s). Read enclosed insert. STORAGE: Store at 8°-27°C (46°-80°F).
Do not refrigerate or store at high temperatures. Keep container tightly closed. © 2000, 2004 Alcon, Inc. ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA Printed in USA H13299-0214 LOT: EXP.:
Medicare Part D spend CMS · PART D · 2026 (Q1)
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |